AI Article Synopsis
- PDMPs and adiponectin are key in the development of atherothrombosis, particularly in patients with high uric acid levels (hyperuricemia).
- After 2 months of febuxostat treatment, uric acid and IL-6 levels decreased significantly, but changes in PDMP and adiponectin levels didn't occur until after 6 months of treatment.
- The findings suggest that febuxostat may help prevent atherothrombosis in hyperuricemic patients by influencing PDMP levels through xanthine oxidase inhibition rather than merely lowering uric acid.
Article Abstract
Platelet-derived microparticles (PDMPs) and adiponectin play an important role in the development of atherothrombosis. We investigated the effect of febuxostat on circulating PDMP levels and adiponectin in hyperuricemic patients. Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment. Plasma levels of PDMPs and biomarkers were higher, while those of adiponectin were lower in hyperuricemic patients than in normouricemic controls. Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment. However, PDMP and biomarkers decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly. These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664023 | PMC |
| http://dx.doi.org/10.1097/MBC.0000000000000335 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!